Email Alerts
Boston Therapeutics, Inc.
Boston Therapeutics, Inc. is a pharmaceutical company focused on the development, manufacture and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in the areas of diabetes and inflammatory diseases.
Latest News
InformationAboutDiabetes.com:
Boston Therapeutics On The Verge of a Blood Sugar Breakthrough - An Interview With CEO Dr. Platt
Boston Therapeutics Article on UnionLeader.com:
CEO says sugar kills, and he's working on a solution
Genetic Engineering & Biotechnology News:
Addressing Unmet Medical Needs with Complex Carbohydrate Chemistry
Featured Products
PAZ320
Blood Glucose Management
Prevention of Diabetes and its complications
- Prevention and Treatment of Type II Diabetes
- Novel, non-systemic appraoch to blood sugar management
- Chewable dose
- See more information »

IpoxynTM
Universal Oxygen Carrier
Prevention of Necrosis & Ischemic conditions
- Injectable continuous IV
- Safe molecule
- No blood-type matching required
- No supplemental oxygen required
- No supply shortages
- See more information »

Press Releases
- Boston Therapeutics Reports First Quarter 2013 Results
May 15 2013, 4:10 PM EDT - Boston Therapeutics Requests an IND Meeting With the FDA for PAZ320 to Reduce Postprandial Hyperglycemia in Type 2 Diabetes
Apr 11 2013, 7:00 AM EDT - Boston Therapeutics Featured in Four Publications
Apr 8 2013, 7:50 AM EDT - Boston Therapeutics Reports Full Year 2012 Financial Results
Apr 4 2013, 4:10 PM EDT - Boston Therapeutics Strategically Positioned to Focus Its Pipeline on Commercializing Pharmaceutical Drugs to Treat Diabetes and Inflammatory Disease: To Accelerate Commercialization of PAZ320 & IPOXYN(TM)
Mar 27 2013, 7:00 AM EDT
